ArticleEuropean journal of cancer (Oxford, England : 1990)2022
An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.
Article in European journal of cancer (Oxford, England : 1990), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Trial
- Ethnic diversity in treatment response for colorectal cancer: proof of concept for radiomics-driven enrichment trials.European radiology · 2023Trial
- Survival benefit of ⁶⁸Ga-FAPI PET/CT staging for prognostic assessment in gastric and colorectal cancer compared with CE-CT and ¹⁸F-FDG PET/CT: a single-center retrospective study.European journal of nuclear medicine and molecular imaging · 2026Article
- AI and the digital pathology revolution: clinical applications in cancer diagnosis and assessment.Expert review of molecular diagnostics · 2026Review
- Future directions of image-guided thermal ablation in colorectal cancer lung oligometastases.World journal of gastroenterology · 2026Article
- Review
- A promptable CT foundation model for solid tumor evaluation.NPJ precision oncology · 2025Article
- Comparison of virtual and true non-contrast images from dual-layer spectral detector computed tomography (CT) in patients with colorectal cancer.Quantitative imaging in medicine and surgery · 2024Article
- Effectiveness of magnetic resonance imaging and spiral computed tomography in the staging and treatment prognosis of colorectal cancer.World journal of gastrointestinal surgery · 2024Article
- Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling.Military Medical Research · 2023Review
- Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy.Journal for immunotherapy of cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND &
aimsQuantitative analysis of computed tomography (CT) scans of patients with metastatic colorectal cancer (mCRC) can identify imaging signatures that predict overall survival (OS).
methodsWe retrospectively analysed CT images from 1584 mCRC patients on two phase III trials evaluating FOLFOX ± panitumumab (n = 331, 350) and FOLFIRI ± aflibercept (n = 437, 466). In the training set (n = 720), an algorithm was trained to predict OS landmarked from month 2; the output was a signature value on a scale from 0 to 1 (most to least favourable predicted OS). In the validation set (n = 864), hazard ratios (HRs) evaluated the association of the signature with OS using RECIST1.1 as a benchmark of comparison.
resultsIn the training set, the selected signature combined three features - change in tumour volume, change in tumour spatial heterogeneity, and tumour volume - to predict OS. In the validation set, RECIST1.1 classified patients in three categories: response (n = 166, 19.2%), stable disease (n = 636, 73.6%), and progression (n = 62, 7.2%). The HR was 3.93 (2.79-5.54). Using the same distribution for the signature, the HR was 21.04 (14.88-30.58), showing an incremental prognostic separation. Stable disease by RECIST1.1 was reclassified by the signature along a continuum where patients belonging to the most and least favourable signature quartiles had a median OS of 40.73 (28.49 to NA) months (n = 94) and 7.03 (5.66-7.89) months (n = 166), respectively.
conclusionsA signature combining three imaging features provides early prognostic information that can improve treatment decisions for individual patients and clinical trial analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.